Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab (Keytruda) is a treatment option when it approved the immunotherapeutic for treating certain patients with cervical cancer and certain patients with non-Hodgkin lymphoma.Read More
Lymphomas are a collection of blood cancers stemming from aberrant lymphocytes, which are critical components of the immune system. Lymphomas are classically divided into two categories – Hodgkin lymphoma (HL), and Non-Hodgkin lymphoma (NHL). It is estimated that over 90 percent of lymphomas are NHL, of which there are many distinct subtypes. Recent statistics estimate that nearly 75,000 new cases of NHL will be diagnosed in 2018.Read More
For many aspiring investigators, pursuing a career in cancer research can be a complex exploration of self and purpose.
In this touching and inspiring piece published in The New York Times, a former AACR Undergraduate Scholar Awardee, Mya Roberson, now a doctoral student at the University of North Carolina Gillings School of Global Public Health, shares how her participation in the AACR Annual Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved helped her realize the meaning in her research.Read More
This week, President Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, which is aimed at supporting pediatric cancer research. The legislation calls for expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.Read More
“We are in a promising time for cancer research and treatment; however, ovarian cancer remains difficult to treat, since it is often not detected until it has reached an advanced …Read More
For cancer patients at the ends of their lives, hospice care can provide access to comfort measures and extra help. Medicare offers hospice benefits to eligible patients. But not all patients have equal access to this care, research indicates.
In the spring issue of Cancer Today, medical and business journalist Charlotte Huff writes about disparities in end-of-life care affecting U.S. cancer patients.Read More
The American Association for Cancer Research (AACR) is proud to support the Scientist↔Survivor Program (SSP), which provides cancer survivors with opportunities to engage in cancer research, survivorship issues, advocacy, and …Read More
Assessing new anticancer therapeutics in clinical trials is a vital step in evaluating the toxicity and efficacy of treatment before its approval for widespread use. Throughout these trials, many patients encounter a variety of side effects, ranging from physical ailments such as nausea or rash to psychological symptoms such as depression or anxiety. While it is standard practice to record clinician-reported outcomes to characterize safety, there is no current standard requirement for the use of patient-reported outcomes (PROs) in cancer clinical trials.Read More
Skin cancer is the most commonly diagnosed cancer in the United States. Every year, about 5 million Americans are treated for various forms of the disease.
Skin cancer types include basal and squamous cell cancers, as well as melanoma, the deadliest form of skin cancer. About 73,870 Americans are expected to be diagnosed with melanoma this year. Survival rates are significantly higher when the disease is diagnosed at its earliest stage.Read More
Multiple myeloma arises in immune cells called plasma cells. It is one of the most commonly diagnosed hematological malignancies in the United States, with more than 30,000 new cases expected in 2018.Read More
Although liver cancer isn’t as prevalent as lung cancer or breast cancer, this cancer is now the fastest-increasing cause of cancer death in the United States. In the Spring 2018 issue of Cancer Today, contributing editor Sue Rochman explored contributing factors for the increased liver cancer incidence since the mid-1970s.Read More